Pancreatic cancer — clinical trials in Denmark

14 open options

TRIALPHASE2RECRUITING
BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
[68Ga]Ga-FAPI-46 — 1 site
TRIALNARECRUITING
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
ctDNA — 5 sites
TRIALPHASE2RECRUITING
Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer
Gemcitabine · Nab paclitaxel — 1 site
TRIALNARECRUITING
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
PALN resection — 6 sites
TRIALPHASE1RECRUITING
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
68Ga-NNS309 · 177Lu-DFC413 — 8 sites
TRIALPHASE1RECRUITING
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
AMG 410 · Pembrolizumab · Panitumumab — 39 sites
TRIALNARECRUITING
Holistic Acupuncture for Patients With Chemotherapy Induced Nausea
Holistic acupuncture and acupressure · Standard medical treatment — 1 site
TRIALPHASE2RECRUITING
Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC.
Propranolol · Placebo — 2 sites
TRIALPHASE2RECRUITING
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Belzutifan — 84 sites
TRIALNARECRUITING
Study of PRO in Patients with Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)
Supportive application with integrated weekly PRO — 1 site
TRIALPHASE2RECRUITING
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
BAY2927088 — 54 sites
TRIALPHASE3RECRUITING
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
INCB161734 · Placebo · Investigator's choice of chemotherapy — 219 sites
TRIALNARECRUITING
Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery
Preoperative MRI — 3 sites
TRIALPHASE1 / PHASE2RECRUITING
Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC
ANOC-001 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles) · ANOC-002 (TCR-T cells targeting KRAS G12V mutation presented by specific HLA alleles) · ANOC-003 (TCR-T cells targeting KRAS G12D mutation presented by specific HLA alleles) — 10 sites

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.